版权所有:内蒙古大学图书馆 技术提供:维普资讯• 智图
内蒙古自治区呼和浩特市赛罕区大学西街235号 邮编: 010021
作者机构:La Fe Univ Hosp Dept Clin Pathol Valencia 46009 Spain La Fe Univ Hosp Res Ctr Valencia 46009 Spain
出 版 物:《THROMBOSIS AND HAEMOSTASIS》 (Thromb. Haemost.)
年 卷 期:1999年第82卷第3期
页 面:1011-1014页
核心收录:
学科分类:1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 10[医学]
主 题:抗凝药/治疗应用 纤维蛋白/缺乏 肝素辅助因子Ⅱ/缺乏 杂合子 纯合子 系谱 表型 妊娠并发症 血液/血液 妊娠并发症 血液/药物疗法 肺栓塞/血液 肺栓塞/遗传学 危险因素 静脉血栓形成/血液 静脉血栓形成/并发症 静脉血栓形成/遗传学 青少年 成年人 儿童 儿童 学龄前 女(雌)性 人类 婴儿 男(雄)性 中年人 妊娠
摘 要:Heparin cofactor II (HCII) is a specific inhibitor of thrombin in the presence of heparin or dermatan sulphate. Although there have been reports on families in which a heterozygous HCII deficiency is associated with thromboembolic events, several epidemiological studies revealed that heterozygous HCII deficiency is as prevalent among healthy subjects as it is among patients with deep venous thrombosis (DVT). It is therefore not yet clear whether HCII is or is not a thrombotic risk factor. We analyze and describe in an extended family the biochemical and genetic thrombophilic risk factors and evaluate the potential thrombotic risk involved in homozygous and heterozygous HCII deficiency, either alone or associated with other thrombotic or circumstantial risk factors. The propositus has had three episodes of DVT and a pulmonary embolism. During the first episode of DVT the patient was diagnosed as having AT deficiency. Later, a functional and antigenic HCII deficiency, compatible with the homozygous form, was detected. The family study shows that both the propositus and her sister have homozygous HCII deficiency and that 12 of the 27 family members have heterozygous HCII deficiency. This is possibly the first case report on a homozygous phenotype for the HCII deficiency with, in addition, partial AT deficiency. The propositus has suffered several thrombotic events, unlike the other 12 family members with heterozygous HCII deficiency and her sister, who is also homozygous for this disorder. We suggest that HCII deficiency may play a limited in vivo role as a thrombotic risk factor unless associated with AT deficiency or another congenital thrombotic risk factor.